Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
5 authors.
Clémence CavaillèsDepartment of Psychiatry and Behavioral Sciences, University of California San Francisco, San Francisco, California, USA.ORCID 0000-0002-8443-2307
Mercedes R CarnethonDepartment of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Kristen L KnutsonDepartment of Neurology and Center for Circadian and Sleep Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Stephen Justin ThomasDepartment of Psychiatry & Behavioral Neurobiology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Kristine YaffeDepartment of Psychiatry and Behavioral Sciences, University of California San Francisco, San Francisco, California, USA.
Funding
CORONARY ARTERY RISK DEVELOPMENT IN YOUNG ADULTS (CARDIA) STUDY - COORDINATING CENTER (CC)75N92023D00002 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LI, JING · 2023 to 2025
$6.8M
Sleep Quality and Mechanistic Links to Alzheimer Disease and Related Disorders among older Mexican Americans and Non-Hispanic WhitesR01AG066137 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI O'BRYANT, SID E, YAFFE, KRISTINE · 2019 to 2023
$4.3M
Population Based Research for Alzheimer's Innovation (POP BRAIN)R35AG071916 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI YAFFE, KRISTINE · 2021 to 2024
$3.8M
Lifecourse CVD Risk and Midlife Cognitive Trajectories and Brain Aging: Implications for Alzheimer's and Dementia PreventionR01AG063887 · NIA · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI YAFFE, KRISTINE · 2019 to 2022
$3.0M
Lifecourse Predictors and Mechanisms of Early Clinical ADRD among Black and White Adults in their SixtiesR01AG091431 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Kristine Yaffe · 2025 to 2026
$2.6M
CORONARY ARTERY RISK DEVELOPMENT IN YOUNG ADULTS (CARDIA) STUDY - OAKLAND FIELD CENTER75N92023D00003 · NHLBI · KAISER FOUNDATION RESEARCH INSTITUTE · PI BHATT, ANKEET S. · 2023 to 2025
$2.2M
CORONARY ARTERY RISK DEVELOPMENT IN YOUNG ADULTS (CARDIA) STUDY - BIRMINGHAM FIELD CENTER75N92023D00005 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LEWIS, CORA · 2023 to 2025
$2.2M
CORONARY ARTERY RISK DEVELOPMENT IN YOUNG ADULTS (CARDIA) STUDY - CHICAGO FIELD CENTERDIVERSITY SUPPLEMENT FOR MORGANN WEST75N92023D00004 · NHLBI · NORTHWESTERN UNIVERSITY · PI CARNETHON, MERCEDES · 2023 to 2025
$2.1M
CORONARY ARTERY RISK DEVELOPMENT IN YOUNG ADULTS (CARDIA) STUDY - UNIVERSITY OF MINNESOTA FIELD CENTER.75N92023D00006 · NHLBI · UNIVERSITY OF MINNESOTA · PI SCHREINER, PAMELA J · 2023 to 2025
$1.7M
Coronary Artery Risk Development in Young Adults Study (CARDIA)National Heart, Lung, and Blood Institute (NHLBI)NHLBI NIH HHS 75N92023D00002NHLBI NIH HHS 75N92023D00003NHLBI NIH HHS 75N92023D00004NHLBI NIH HHS 75N92023D00005NHLBI NIH HHS 75N92023D00006NIA NIH HHS R01 AG063887NIA NIH HHS R01AG063887NIA NIH HHS R01 AG066137NIA NIH HHS R01 AG091431NIA NIH HHS R35 AG071916NIA NIH HHS R35AG071916
6 · The paper itself
Abstract
introductionPoor sleep characteristics are associated with Alzheimer's disease (AD) among older adults; however, this relationship remains underexplored earlier in life. We investigated how early midlife sleep relates to AD-related biomarkers in late midlife.
methodsA total of 1325 adults (mean age = 40.3 years) self-reported sleep quality, sleep duration, daytime sleepiness, and insomnia symptoms. Twenty years later, we assessed plasma amyloid beta (Aβ)42/40, tau phosphorylated at threonine 217 (p-tau217), neurofilament light chain (NfL), and magnetic resonance imaging (MRI)-derived Spatial Pattern of Abnormality for Recognition of Early AD (SPARE-AD), characterizing AD-like brain atrophy.
resultsAfter multivariable adjustment, longer sleep duration was associated with lower Aβ42/40, poor sleep quality with higher NfL, daytime sleepiness with both lower Aβ42/40 and higher NfL, and insomnia symptoms with higher SPARE-AD. No associations were observed with sleep and p-tau217. DISCUSSION: Poor sleep in early midlife was associated with unfavorable AD biomarker levels 20 years later, supporting the idea of sleep as a potential modifiable AD risk factor.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Midlife sleep characteristics and Alzheimer's disease biomarkers 20 years later. · full record | Socratic